Skip to main content

Table 7 Comparison between patients with elevated post-treatment METTL3 gene expression versus patients with lowered post-treatment gene levels regarding BM blast counts in follow-up samples

From: Methyltransferase-like 3 gene (METTL3) expression and prognostic impact in acute myeloid leukemia patients

BM blast counts% AML group with elevated normalized METTL3 gene expression post-treatment (n = 9) AML group with reduced normalized METTL3 gene expression post-treatment (n = 6) χ2 p value
No % No %
Assessment of maintenance of CR
 2nd month BM blast counts%
  ≤ 5% 4 44.4% 6 100.0% 3.905 0.048*
  > 5% 5 55.6% 0 0.0%   
 4th month BM blast counts%
  ≤ 5% 2 22.2% 6 100.0% 5.904 0.015*
  > 5% 7 77.8% 0 0.0%   
 6th month BM blast counts%
  ≤ 5% 2 22.2% 6 100.0% 5.904 0.015*
  > 5% 7 77.8% 0 0.0%   
  1. CR complete remission, BM bone marrow, χ2 Chi-square test
  2. *p value < 0.05 S